Mainstream Capital Management
PYXS icon

Mainstream Capital Management’s Pyxis Oncology PYXS Stock Holding History

Mainstream Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$466 Buy
+200
New +$605 ﹤0.01% 281
2025
Q1 		– Sell
-200
Closed -$312 – 241
2024
Q4 		$312 Buy
+200
New +$577 ﹤0.01% 315

Other funds holding PYXS

T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $159M AUM 18.68% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
First United Bank & Trust
First United Bank & Trust Oakland, Maryland $347M AUM 18.04% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Mainstream Capital Management's PYXS Position: Q3 2026 in Review

Mainstream Capital Management opened a new position in Pyxis Oncology (PYXS) in Q3 2026: 200 shares worth $466. The stake represents ﹤0.01% of the portfolio and ranks #281 among its holdings. This is a return to the name: Mainstream Capital Management previously reported a position in PYXS as recently as Q4 2024.

Mainstream Capital Management first reported a position in PYXS in Q4 2024 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.

  • Mainstream Capital Management held 200 shares of Pyxis Oncology worth $466 as of Q3 2026.
  • Pyxis Oncology was a new Mainstream Capital Management position in Q3 2026.
  • Pyxis Oncology made up ﹤0.01% of Mainstream Capital Management's portfolio in Q3 2026, its #281 holding.
  • Mainstream Capital Management first reported a position in Pyxis Oncology in Q4 2024 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.

Based on Mainstream Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.